ACTR-90. ROLE OF PHOTODYNAMIC THERAPY (PDT) USING TALAPORFIN SODIUM AND SEMICONDUCTOR LASER ON PROGNOSIS OF PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA

Abstract

BACKGROUND: Photodynamic therapy (PDT) is an emerging therapy that utilizes biochemical reactions between photosensitizer, light and tissue oxygen. PDT using Talaporfin sodium and semiconductor laser has shown dramatic anti-tumor effects for various cancers including lung cancer and esophageal cancer in Japan. We have conducted a prospective phase II trial of PDT for malignant brain tumors between 2009 and 2012, and PDT was approved for primary malignant brain tumors in 2013 in Japan. Since the approval, our institute has performed a prospective observation study of PDT for patients with newly diagnosed glioblastoma. Here, we report the clinical results of this prospective study. METHODS: Patients with newly diagnosed glioblastoma who were treated with surgical removal of the tumor and PDT between March, 2009 and December 2016 were enrolled in this study. We compared the clinical results with patients with newly diagnosed glioblastoma who were treated with surgical removal of the tumor without PDT in same periods. RESULTS: Clinical results of 30 patients in the PDT group (15 males and 15 females) and 162 patients in the control group (102 males and 60 females) were analyzed. Patients who underwent biopsy was excluded. Median age of PDT and control group was 57 and 61 year old, respectively. EOR of the enhanced lesion was not significantly different in the two groups. The median progression free survival (PFS) of the PDT and the control group was 19.6 months and 8.9 months, respectively, and PDT group showed statistically significant better PFS (P=0.023). The median overall survival (OS) was significantly loner (P=0.037) in the PDT group (27.4 month) than the in the control group (22.1 months). There was no significant symptomatic adverse effect in the PDT group. CONCLUSION: PDT appears to provide significant survival benefit in patients with newly diagnosed glioblastoma. A randomized clinical trial is warranted.